Caveolins in the repair phase of acute renal failure after oxidative stress

Nephrology

Volumn 9, Issue 6, 2004, Pages 374-380

  Percy, Christine ^a   Waters, Michael J ^a   Gobé, Glenda ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Caveolae; Caveolin; Kidney; Oxidative stress

Indexed keywords

CALCIUM; CAVEOLIN; CAVEOLIN 1; CAVEOLIN 2; CERAMIDE; CHOLESTEROL; FREE RADICAL; HEME OXYGENASE; NITRIC OXIDE;

ACUTE KIDNEY FAILURE; APOPTOSIS; CAVEOLA; CELL DAMAGE; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CYTOSKELETON; HUMAN; INTOXICATION; ISCHEMIA; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CAVEOLAE; CAVEOLINS; CYTOSKELETON; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 12244297805     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00356.x     Document Type: Review

References (66)

1. Mutlu G, Abbasoglu L, Dogru-Abbasoglu S, Solakoglu S, Bulut M. Morphologic changes and lipid peroxidation in renal tissues of young rats following intestinal ischemia-reperfusion. Pediatr. Surg. Int. 2002; 18: 337-40.
2. Zager RA, Johnson A, Hanson S, del Rosa V. Altered cholesterol localization and caveolin expression during the evolution of acute renal failure. Kidney Int. 2002; 61: 1674-83.
3. Mahmoudi M, Willgoss D, Cuttle L et al. In vivo and in vitro models demonstrate a role for caveolin-1 in the pathogenesis of ischaemic acute renal failure. J. Pathol 2003; 200: 396-405.
4. Parton RG. Caveolae - from ultrastructure to molecular mechanisms. Nat. Rev. Mol. Cell Biol. 2003; 4: 162-7.
5. Razani B, Woodman SE, Lisanti MP. Caveolae: From cell biology to animal physiology. Pharmacol. Rev. 2002; 54: 431-67.
6. Cao G, Yang G, Timme T et al. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalcuria and urolithiasis. Am. J. Pathol. 2003; 162: 1241-8.
7. Woodman S, Cheung M, Tarr M et al. Urogenital alterations in aged male caveolin-1 knockout mice. J. Urol. 2004; 171: 950-7.
8. Razani B, Wang XB, Engelman JA et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol. Cell. Biol. 2002; 22: 2329-44.
9. Lahtinen U, Honsho M, Parton RG, Simons K, Verkade P. Involvement of caveolin-2 in caveolar biogenesis in MDCK cells. FEBS Lett. 2003; 538: 85-8.
10. Drab M, Verkade P, Elger M et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293: 2449-52.
11. Parton RG. Life without caveolae. Science 2001; 293: 2404-5.
12. Woodman SE, Cheung MW-C, Tarr M et al. Urogenital alterations in aged male caveolin-1 knockout mice. J. Urol. 2004; 171: 950-7.
13. Park DS, Cohen AW, Frank PG et al. Caveolin-1 null (-/-) mice show dramatic reductions in life span. Biochemistry 2003; 42: 15124-31.
14. Wyse BD, Prior IA, Qian H et al. Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but does not at the plasma membrane. J. Biol. Chem. 2003; 278: 23 738-46.
15. Sotgia F, Razani B, Bonuccelli G et al. Intracellular retention of glycosylphosphatidyl inositol-linked proteins in caveolin-deficient cells. Mol. Cell. Biol. 2002; 22: 3905-26.
16. Razani B, Combs TP, Wang XB et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 2002; 277: 8635-47.
17. Park DS, Lee H, Frank PG et al. Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol. Biol. Cell 2002; 13: 3416-30.
18. Park DS. Functional recovery of senescent cells through restoration of receptor-mediated endocytosis. Mech. Ageing Dev. 2002; 123: 917-26.
19. Tamai O, Oka N, Kikuchi T et al. Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis. Kidney Int. 2001; 59: 471-80.
20. Fong A, Garcia E, Gwynn L, Lisanti MP, Fazzari MJ, Li M. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 2003; 120: 93-100.
21. Fiucci G, Ravid D, Reich R, Liscovitch M. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002; 21: 2365-75.
22. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 1997; 272: 16 374-81.
23. Galbiati F, Volonté D, Engelman JA et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 1998; 17: 6633-48.
24. Cho KA, Ryu SJ, Park JS et al. Senescent phenotype can be reversed by reduction of caveolin status. J. Biol. Chem. 2003; 278: 27 789-95.
25. Liu J, Wang XB, Park DS, Lisanti MP. Caveolin-1 expression enhances endothelial capillary tubule formation. J. Biol. Chem. 2002; 277: 10 661-8.
26. Griffoni C, Spisni E, Santi S, Riccio M, Guarnieri T, Tomasi V. Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem. Biophys. Res. Commun. 2000; 276: 756-61.
27. Vogel U, Sandvig K, Van Deurs B. Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells. J. Cell Sci. 1998; 111: 825-32.
28. Fielding CJ, Fielding PE. Caveolae and intracellular trafficking of cholesterol. Adv. Drug Deliv. Rev. 2001; 49: 251-64.
29. Liu J, Lee P, Galbiati F, Kitsis RN, Lisanti MP. Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am. J. Physiol. Cell Physiol. 2001; 280: C823-35.
30. Nony PA, Schnellmann RG. Mechanisms of renal cell repair and regeneration after acute renal failure,. J. Pharmacol. Exp. Ther. 2003; 304: 905-12.
31. Simons K, Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000; 1: 31-41.
32. Van Deurs B, Roepstorff K, Hommelgaard AM, Sandvig K. Caveolae: Anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol. 2003; 13: 92-100.
33. Isshiki M, Anderson RGW. Calcium signal transduction from caveolae. Cell Calcium 1999; 26: 201-8.
34. Fielding CJ, Fielding PE. Relationship between cholesterol trafficking and signaling in rafts and caveolae. Biochim. Biophys. Acta 2003; 1610: 219-28.
35. 1 phase of the cell cycle. Mol. Cell. 2001; 8: 115-27.
36. Mundy DI, Machleidt T, Ying Y, Anderson RGW, Bloom GS. Dual control of caveolar membrane traffic by microtubules and the actin cytoskeleton. J. Cell Sci. 2002; 115: 4327-39.
37. Venema RC. Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int. Immunopharmacol. 2002; 2: 1755-62.
38. Ko Y, Lee J, Hang J, Ahn J, Seo J. TNF-a-mediated apoptosis is initiated in caveolae-like domains. J. Immunol. 1999; 162: 7217-23.
39. Yamaguchi T, Murata Y, Fujiyoshi Y, Doi T. Regulated interaction of the endothelin B receptor with caveolin-1. Eur. J. Biochem. 2003; 270: 1816-27.
40. Massimino ML, Griffoni C, Spisni E, Toni M, Tomasi V. Involvement of caveolae and caveolae-like domains in signaling cell survival and angiogenesis. Cell. Signal. 2002; 14: 93-8.
41. Liu P, Ying Y, Ko Y, Anderson RGW. Localization of Platelet-Derived Growth Factor-stimulated phosphorylation cascade to caveolae. J. Biol. Chem. 1996; 271: 10 299-303.
42. Lehto V. EGF receptor: Which way to go? FEBS Lett. 2001; 491: 1-3.
43. Chen J, Braet F, Brodsky S et al. VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am. J. Physiol (Cell Physiol.) 2002; 282: C1053-63.
44. Di Guglielmo GM, Roy CL, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-β receptor signaling and turnover. Nat. Cell Biol. 2003; 5: 410-21.
45. Fujimoto T. Calcium pump of the plasma membrane is localized in caveolae. J. Cell Biol. 1993; 120: 1147-57.
46. Fujimoto T, Miyawaki A, Mikoshiba K. Inositol 1,4,5-triphosphate receptor-like protein in plasmalemmal caveolae is linked to actin filaments. J. Cell Sci. 1995; 108: 7-15.
47. Felley-Bosco E, Bender FC, Courjault-Gautier F, Bron C, Quest AFG. Caveolin-1 downregulates inducible nitric oxide synthase via the proteasome pathway in human colon carcinoma cells. Proc. Natl Acad. Sci. USA 2000; 97: 14 334-9.
48. Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 1997; 272: 28 563-7.
49. Nakashima S. Protein kinase Cα (PKCα): Regulation of biological function,. J. Biochem. 2002; 132: 669-75.
50. Kowaltoski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic. Biol. Med. 1999; 26: 463-71.
51. 2+ exchanger and endothelin-1 overproduction in ischaemia/reperfusion-induced acute renal failure. Clin. Sci. 2002; 103: 8389-92.
52. Ortiz PA, Garvin JA. Cardiovascular and renal control in NOS-deficient mouse models. Am. J. Physiol. Regul. (Integr. Comp. Physiol.) 2003; 284: R628-38.
53. García-Cardeña G, Martasek P, Masters BSS et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. J. Biol. Chem. 1997; 272: 25 437-40.
54. Rhoden EL, Rhoden CR, Lucas ML, Pereira-Lima L, Zettter C, Belló-Klein A. The role of nitric oxide pathway in the renal ischemia-reperfusion injury in rats. Transpl. Immunul. 2002; 10: 277-84.
55. Albrecht EWJA, Stegeman CA, Heeringa P, Henning RH, Van Goor H. Protective role of endothelial nitric oxide synthase. J. Pathol. 2003; 199: 8-17.
56. Romiti E, Meacci E, Tanzi G, Becciolini L, Mitsutake S, Ito M, Bruni P. Localization of neutral ceramidase in caveolin-enriched light membranes of murine endothelial cells. FEBS Lett. 2001; 506: 163-8.
57. Zager RA, Conrad S, Lochhead K, Sweeney EA, Igarashi Y, Burkhart KM. Altered sphingomyelinase and ceramide expression in the setting of ischemic and nephrotoxic acute renal failure. Kidney Int. 1998; 53: 573-82.
58. Zager RA, Andoh T, Bennett WM. Renal cholesterol accumulation: A durable response after acute and subacute renal insults. Am. J. Pathol. 2001; 159: 743-52.
59. Zager RA, Johnson A, Anderson K, Wright S. Cholesterol ester accumulation: An immediate consequence of acute in vivo ischemic renal injury. Kidney Int. 2001; 59: 1750-61.
60. Lavie Y, Fiucci G, Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: Functional implications. Adv. Drug Deliv. Rev. 2001; 49: 317-23.
61. Uittenbogaard A, Smart EJ. Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J. Biol. Chem. 2000; 275: 25 595-9.
62. Wang P, Liu P, Weng J, Sontag E, Anderson RGW. A cholesterol-regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity. EMBO J. 2003; 22: 2658-67.
63. Akagi R., Takahashi T, Sassa S. Fundamental role of heme oxygenase in the protection against ischemic acute renal failure. Jpn. J. Pharmacol. 2002; 88: 127-32.
64. Jung N, Kim HP, Kim B et al. Evidence for heme oxygenase-1 association with caveolin-1 and-2 in mouse mesangial cells. IUBMB Life 2003; 55: 525-32.
65. Lee HT, Xu H, Ota-Setlik A, Emala CW. Oxidant preconditioning protects human proximal tubular cells against lethal oxidant injury via p38 MAPK and heme oxygenase-1. Am. J. Nephrol. 2003; 23: 324-33.
66. Morse D, Choi AMK. Heme oxygenase-1: The 'emerging molecule' has arrived. Am. J. Respir. Cell Mol. Biol. 2002; 27: 8-16.